"Todd Blanche, the acting attorney general, signed an order that removes products sold under state medical cannabis licenses and FDA approved cannabis products from schedule I to schedule III, which includes legal but regulated substances. This change raises questions for the cannabis industry regarding its implications."
"Cat Packer, director of drug markets and legal regulation at the Drug Policy Alliance, stated that while some marijuana-related products are no longer treated as schedule I, it is not accurate to say marijuana has been broadly rescheduled. This is partial rescheduling, at best."
"The order justifies the partial move by repeatedly citing the Single Convention on Narcotic Drugs, a UN treaty that requires specified narcotics, including cannabis, to be produced only in limited quantities for scientific and medical purposes."
The Trump administration has partially rescheduled cannabis, moving state medical cannabis and FDA-approved products from schedule I to schedule III. This change does not broadly reschedule marijuana, as it only applies to future FDA-approved products. Existing FDA-approved cannabis pharmaceuticals remain unaffected. Concerns arise regarding the potential predetermination of future scheduling outcomes without comprehensive evaluations. The administration cites the Single Convention on Narcotic Drugs to justify this partial rescheduling, highlighting a debate on the alignment of U.S. cannabis policy with international treaties.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]